Arena Pharmaceuticals’ board of directors is getting its way: CEO Jack Lief is hitting the road.
On Monday, Lief retired from the company at the board’s request, the California drugmaker said in an SEC filing. Among the benefits he’ll take with him: A $1.8 million cash severance payment, 18 months of continued health insurance coverage, and acceleration of the stock options and RSUs that would have vested over the next year and a half.
Harry Hixson, one of the company’s directors, will fill in while Arena looks for a replacement.
Lief, who cofounded Arena, has “contributed in many ways” since launching the company in 1997, Hixson said in a statement, overseeing the approval and rollout of obesity therapy Belviq and developing “a robust clinical stage pipeline and productive research platform.”
Yet investors cheered the news of his departure following the announcement, sending shares up 5.1%.
The search for a more permanent stand-in will begin immediately, Arena said–and whoever lands in Lief’s old spot will have their job cut out for them. Belviq and rival Qsymia from Vivus recently ceded the top spot in the market for weight-loss meds to new challenger Contrave from Orexigen.
It’s not too late for Belviq to get back in the game, however: As of the week ended Sept. 11, Contrave held 38% of the market, with Belviq holding down the No. 2 spot with 30% and Qsymia, at 27%, bringing up the rear.
But if it wants to stage a comeback, it’ll have to do so with a sales force one-third the size of the one Orexigen’s marketing partner, Takeda, has on the ground. Eisai, Arena’s own partner, currently has 300 reps in the field–a tally that pales in comparison to the 900-rep army Takeda can boast.
By Carly Helfand
Source: Fierce Pharma
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
